
Krystal Biotech (KRYS) Stock Forecast & Price Target
Krystal Biotech (KRYS) Analyst Ratings
Bulls say
Krystal Biotech Inc. reported a significant revenue increase for its product Vyjuvek, achieving $91.1 million in net revenue for the third quarter of FY24, representing a 9% rise from the previous quarter, with full-year revenues reaching $290.5 million in line with projections. The company is also showing promising preclinical results for its gene therapies and anticipates a pickup in approval rates for additional products beginning in 2025, further supporting its growth potential. With strong patient compliance and discussions around implementing a share repurchase program, Krystal Biotech appears well-positioned for profitability and may even explore dividend opportunities in the future.
Bears say
Krystal Biotech Inc. faces a negative outlook due to several fundamental challenges, including a downward trend in new reimbursement approvals, with projections indicating a decline from 70 new adds in 2Q24 to just 50 in 4Q24. Additionally, the competitive landscape in the gene therapy sector remains precarious, as the company could encounter significant recruitment difficulties for clinical trials due to the rarity of the diseases it targets, compounded by the complexities of manufacturing novel gene therapy products. Moreover, potential setbacks in clinical trials, unforeseen safety issues, and the necessity for adequate funding to advance its drug development may further impede the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of Krystal Biotech and is not a guaranteed prediction by Public.com or investment advice.
Krystal Biotech (KRYS) Analyst Forecast & Price Prediction
Start investing in Krystal Biotech (KRYS)
Order type
Buy in
Order amount
Est. shares
0 shares